Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of INC280 with Food in cMET Dysregulated Solid Tumors
NCT02925104Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2016
- Primary completion
- May 2018
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 8
01
Overview
Phase 1, open-label, single-arm trial of capmatinib in solid tumor (advanced stage), sponsored by Novartis. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Frequency of Dose Limiting Toxicities at 28 days and 5 more. Started Dec 2016; status: completed.
02
Drugs
capmatinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02925104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02925104.